Northwest Biotherapeutics (NWBO) Payables (2010 - 2026)

Northwest Biotherapeutics' Payables history runs 17 years deep, the most recent figure standing at $43.2 million for Q1 2026.

• In Q1 2026, Payables rose 98.46% year-over-year to $43.2 million; the TTM figure through Mar 2026 stood at $43.2 million (up 98.46% YoY), while the FY2025 annual figure was $40.3 million, up 109.94% from the prior year.
• Payables for Q1 2026 stood at $43.2 million, up from $40.3 million in the prior quarter.
• The five-year high for Payables was $106.3 million in Q1 2022, with the low at $11.2 million in Q4 2023.
• The 5-year median for Payables is $25.5 million (2024), against an average of $35.9 million.
• The sharpest annual moves came in 2022 and 2023: Payables surged 372.24% in 2022, then slumped 87.46% in 2023.
• Northwest Biotherapeutics' Payables stood at $26.1 million in 2022, then slumped by 57.12% to $11.2 million in 2023, then surged by 71.51% to $19.2 million in 2024, then soared by 109.94% to $40.3 million in 2025, then climbed by 7.32% to $43.2 million in 2026.
• Business Quant data shows NWBO's Payables at $43.2 million in Q1 2026, $40.3 million in Q4 2025, and $40.4 million in Q3 2025.